

EXHIBIT 22

Unknown

From: Wayne Geller
Sent: Monday, September 18, 2000 6:27 PM
To: G=Dorothee; G=Liz
Cc: G=Safety; G=Joy; G=Vikram
Subject: Re: FW: Quetiapine and glucose metabolism disorders

Attachments: SeroquelSERMDMDKAPositionPaper.doc

Dear Liz and Dorothee,

Attached is a position paper based upon my presentation at the last SERM meeting on diabetes mellitus, diabetic ketoacidosis, and non-ketotic hyperosmolar coma. Please feel free to contact me if you have any additional questions.

Thanks and kind regards,
Wayne



SeroquelSERMDMD
KAPositionPaper...

Thanks,
Wayne

To: Wayne Geller/HQ/Astra Merck
cc: /G=Dorothee/S=Wientjes/O=Astra Pharmaceutica BV/P=Astra/A=400NET/C=NL, /G=Safety/S=Mailbox/O=Astra Pharmaceutica BV/P=Astra/A=400NET/C=NL, /G=Joy/I=JA/S=Gulliford/OU=ALDERLEY/O=PHARMS/P=ZENECA/A=TMAILUK/C=GB
From: Liz Smith @ X400
Date: 09/18/2000 11:51 AM GDT
Subject: FW: Quetiapine and glucose metabolism disorders

Message

Dear Wayne

Please find attached below a request from the Dutch regulatory authorities about Seroquel.

I would be grateful if you could reply direct to Dorothee since I am out of the office after tomorrow, and Mary O'Hare is also out of the office this week.

With many thanks and kind regards,

Liz

From: Wientjens, Dorothee (temp. employee)
Sent: 18 September 2000 08:53
To: Smith, Liz EH
Cc: O'Hare, Mary M; Hyde, Margaret EM; Gulliford, Joy JA; Whittaker, Denise D -

R&D

Subject: FW: Quetiapine and glucose metabolism disorders

Dear Mailbox,

Please find enclosed a letter from the Dutch authorities concerning Quetiapine and glucose metabolism.

I would be most grateful if you could address his request.

Thank you in advance

Dorothee PWM Wientjens

DSO

AstraZenecaNL

-----Oorspronkelijk bericht-----

Van: Meiners, dhr. drs. A.P. [mailto:ap.meiners@cbg-meb.nl]

Verzonden: dinsdag 5 september 2000 15:35

Aan: Wientjens Dorothee (temp. employee)

Onderwerp: Quetiapine and glucose metabolism disorders

Dear Dorothee,

At a recent pharmacovigilance working party a signal was raised for one of the other atypical antipsychotic drugs in relation to glucose metabolism disorders. Looking at our recent PSUR assessment reports we don't seem to have recognised this with Seroquel, however, increases in weight and blood lipids are recognised, so it would not seem impossible. A formal request for an overview and assessment report on all reports of glucose metabolism disorders associated with quetiapine use is coming your way as part of conclusions of assessment of a type II variation application currently under review, but to expedite matters I am also already sending you this request by e-mail. Would it be possible to submit such a report on short notice. It probably doesn't have to be very extensive as it only focusses on a single issue and it could well be that the number of reports is very limited (even if it would require searching your database for terms such as glucose metabolism disorder, glucose increased, hyperglycemia, diabetes, hypoglycemia, etc.)

Sincerely,

Arthur P. Meiners, head of pharmacovigilance
Medicines Evaluation Board
Kalvermarkt 53 PoBox 16229
2500 BE The Hague
Netherlands
tel +31(70)3567492
fax +31(70)3567515
mailto:ap.meiners@cbg-meb.nl